At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
quetiapine (Seroquel XR)drug
Likely dose
quetiapine (Seroquel XR) 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Brain Imaging of Quetiapine Response in Anxious Depression
In Brief
A Phase 4 clinical trial evaluating quetiapine (Seroquel XR) for Major Depression. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to find out what parts of the brain have increased or decreased connectivity when people are depressed and how Seroquel extended release (XR) changes this connectivity in depressed patients. The genetic samples collected are to look at variation in a gene (serotonin transporter gene), which affects the functioning of the chemical serotonin in the brain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depression
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
First PostedSep 2009
Primary CompletionMar 2012
TodayJul 2026
First PostedSep 23, 2009
Enrollment StartMar 1, 2009
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 16.8 years ago
Interventions
quetiapine (Seroquel XR)drug
Seroquel XR (starting dose 100mg and increased up to 400 mg as tolerated) treatment.